(NewsDirect)
By Julian Richard, Benzinga
BioRestorativeTherapies (NASDAQ: BRTX), a clinical-stage biotechnologycompany focused on stem cell-based therapies, announced on the 8th ofFebruary that the European Patent Office had issued a notice ofallowance for a patent application related to its metabolicThermoStem® program. The Notice of Allowance signals the end of theexamination process for the patent application. It indicates that theEuropean Patent Office has determined that the ThermoStem® program isnovel, non-obvious, and fully and particularly described in the patentapplication.
TheNotice of Allowance is a testament to BioRestorative’s commitment toinnovation and advancing medical science through developing noveltherapies utilizing adult stem cells. With this milestone,BioRestorative has made significant strides toward achieving itsmission of developing and commercializing cell-based products andtherapeutics for various metabolic conditions – such as diabetes andobesity – across key international markets. This patent will providethe company with protection for its proprietary ThermoStem® process,which is being developed for the treatment of metabolicsyndrome.
Metabolicsyndrome is a cluster of conditions, such as obesity andincreased cholesterol (fat) and glucose in the blood, that increasethe risk of type 2 diabetes, heart disease and stroke. TheThermoStem® program harnesses the body’s ability to create newbrown fat tissue from human brown adipose-derived stem cells. Pioneeringresearch conducted by Biorestorative Therapies demonstratedthat brown tissue burns rather than stores energy. Increased levels ofbrown tissue support weight loss by increasing metabolism and reducingsugar and fats in the blood. Thus, higher brown fat levels may addressmetabolic syndrome's significant effects.
Obesity management isthe subject of intenseclinical development with Eli Lilly Co (NYSE: LLY) and Pfizer Inc (NYSE: PFE) looking to emulate the successof Semaglutide, marketed by Novo Nordisk A/S (NYSE: NVO) for the treatment of obesity and type 2diabetes.
“Ourpatent family for our ThermoStem® program continues to grow as wereceive additional patent grants in key markets,” said LanceAlstodt, CEO of BioRestorative Therapies, commenting on thedevelopment. “We are committed to the development of ThermoStem® asa potential treatment for obesity and metabolic disorders, such astype 2 diabetes. This patent, which covers a manufacturing process forThermoStem® developed by BioRestorative’s scientists, enhances ourability to do so in European jurisdictions.”
In addition to itsmetabolic program (ThermoStem®), BioRestorative Therapies ispioneering the use of a patient’s bone marrow cells to treat chroniclower back pain caused by degenerative disc disease. BRTX-100 iscurrently being evaluated as a non-invasive alternative to surgery inpatients with degenerative chronic lower back pain, with results fromthe clinical study expected in Marchor April 2023 .
Visit https://www.biorestorative.com for more information on the company and its product candidates.
This articleoriginally appeared on Benzinga here .
BioRestorativeTherapies was founded by scientists and researchers committed todeveloping stem cell therapies to address unmet needs in patients withhighly prevalent conditions.Our advances in stem cell biology anddelivery protocols harbor great promise in conditioning our bodies’own regenerative potential to treat major diseases more effectivelythan current interventions.Today, BioRestorative is activelydeveloping programs that aim to dramatically increase quality of carefor both (i) chronic back pain caused by disc degeneration, as well as(ii) metabolic disorders including obesity anddiabetes.
This post contains sponsored advertisingcontent. This content is for informational purposes only and is notintended to be investing advice.
ContactDetails
Investor Relations
CompanyWebsite
https://www.biorestorative.com/
Copyright (c) 2023 TheNewswire - All rights reserved.